{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:13:50Z","timestamp":1784099630328,"version":"3.55.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prior drug safety studies investigating the risk of neuropsychiatric events (NPEs) after montelukast initiation have been limited by methodological issues, including incomplete confounder control and unmeasured outcomes associated with completeness of structured data, as well as events recorded only in unstructured clinical notes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the value associated with using linked claims and electronic health records (EHRs) (structured and unstructured data) while investigating the risk of any NPE among patients with asthma initiating montelukast compared with inhaled corticosteroids (ICSs).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used Oracle EHR Real-World Data linked to a national US claims dataset (July 1, 2015, to June 30, 2022) to identify patients aged 6 to 80 years with asthma newly initiating montelukast or ICSs. The data were analyzed between December 13, 2022, and August 2, 2024.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome of any NPE and covariates was assessed using the incremental addition of each data source: analysis 1, claims-only data; analysis 2, claims plus structured EHR data; and analysis 3, claims plus structured and unstructured EHR data. Cox proportional hazard regression models using propensity score\u2013matched cohorts across data sources were used to examine the risk of any NPE by treatment initiation group.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 109\u202f076 patients (mean [SD] age at treatment initiation, 28.8 [20.5] years, 59.4% female), 39\u202f665 (36.4%) initiated montelukast and 69\u202f411 (63.6%) ICSs. Incidence rates per 100 person-years of the first postindex NPE increased with additional data sources for both montelukast and ICS users (analysis 1, 17.11 [95% CI, 16.86-17.36] vs 15.57 [95% CI, 15.34-15.80], respectively; analysis 2, 19.10 [95% CI, 18.83-19.38] vs 18.23 [95% CI, 17.97-18.50], respectively; analysis 3, 27.78 [95% CI, 27.43-28.13] vs 27.40 [95% CI, 27.06-27.75], respectively). Hazard ratios were attenuated across contributing data sources for analysis 1 (1.08 [95% CI, 1.05-1.11]), analysis 2 (1.04 [95% CI, 1.01-1.06]), and analysis 3 (1.01 [95% CI, 1.00-1.03]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that clinical information from linked claims and structured and unstructured EHR data was associated with enriched measurement of patient and disease characteristics and enhanced completeness of evidence vs claims data alone. The findings, however, did not differ substantially across the incrementally contributing data sources or from prior studies. Drug safety and effectiveness studies should integrate information using clinical notes from EHRs with consideration of potential limitations, challenges, and necessary validation processes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.58433","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:30:25Z","timestamp":1770913825000},"page":"e2558433","source":"Crossref","is-referenced-by-count":1,"title":["Use of Clinical Notes to Assess Neuropsychiatric Events After Montelukast Initiation"],"prefix":"10.1001","volume":"9","author":[{"given":"Dena H.","family":"Jaffe","sequence":"first","affiliation":[{"name":"Oracle Health, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Berliner","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget L.","family":"Balkaran","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Yue","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Finlayson","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Guijon","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Orange County, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Chu","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Orange County, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Ehwerhemuepha","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Orange County, Orange, California"},{"name":"Department of Pediatrics, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Seluk","sequence":"additional","affiliation":[{"name":"National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[{"name":"National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly J.","family":"Dandreo","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi J.","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Dutcher","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jummai","family":"Apata","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal T.","family":"Jones","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ma","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie (Jenni)","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"7","key":"zoi251558r3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMp0905338","article-title":"The new Sentinel Network\u2013improving the evidence of medical-product safety.","volume":"361","author":"Platt","year":"2009","journal-title":"N Engl J Med"},{"issue":"e1","key":"zoi251558r5","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1093\/jamia\/ocv130","article-title":"Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance.","volume":"23","author":"Wei","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"zoi251558r6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40471-014-0027-z","article-title":"Misclassification in administrative claims data: quantifying the impact on treatment effect estimates.","volume":"1","author":"Funk","year":"2014","journal-title":"Curr Epidemiol Rep"},{"issue":"12","key":"zoi251558r7","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/pds.5346","article-title":"Drug exposure misclassification in pharmacoepidemiology: sources and relative impact.","volume":"30","author":"Hempenius","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi251558r8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/aje\/kwae226","article-title":"A future of data-rich pharmacoepidemiology studies: transitioning to large-scale linked EHR + claims data.","volume":"194","author":"Schneeweiss","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"11","key":"zoi251558r9","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/aje\/kwae102","article-title":"A simulation-based bias analysis to assess the impact of unmeasured confounding when designing nonrandomized database studies.","volume":"193","author":"Desai","year":"2024","journal-title":"Am J Epidemiol"},{"issue":"1","key":"zoi251558r10","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooae008","article-title":"smdi: An R package to perform structural missing data investigations on partially observed confounders in real-world evidence studies.","volume":"7","author":"Weberpals","year":"2024","journal-title":"JAMIA Open"},{"issue":"4","key":"zoi251558r11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cpt.2979","article-title":"Six years of the US Food and Drug Administration\u2019s Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: implications for real world evidence generation.","volume":"114","author":"Maro","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi251558r12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaip.2020.07.052","article-title":"Risk of psychiatric adverse events among montelukast users.","volume":"9","author":"Sansing-Foster","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"zoi251558r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23996","article-title":"Youth suicide and preceding mental health diagnosis.","volume":"7","author":"Chaudhary","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi251558r14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jaci.2012.04.035","article-title":"Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study.","volume":"130","author":"Schumock","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"zoi251558r15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaci.2009.08.011","article-title":"Analysis of behavior-related adverse experiences in clinical trials of montelukast.","volume":"124","author":"Philip","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"zoi251558r16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3109\/02770903.2013.823445","article-title":"Antidepressant medication dispensing among montelukast initiators.","volume":"50","author":"Zhou","year":"2013","journal-title":"J Asthma"},{"key":"zoi251558r17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jpeds.2019.02.009","article-title":"Montelukast and neuropsychiatric events in children with asthma: a nested case-control study.","volume":"209","author":"Glockler-Lauf","year":"2019","journal-title":"J Pediatr"},{"issue":"5","key":"zoi251558r18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1176\/appi.ajp.2011.11071009","article-title":"Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care.","volume":"169","author":"Fardet","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"2","key":"zoi251558r19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00148-2017","article-title":"Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.","volume":"50","author":"Benard","year":"2017","journal-title":"Eur Respir J"},{"key":"zoi251558r20","doi-asserted-by":"publisher","first-page":"AB220","DOI":"10.1016\/j.jaci.2018.12.672","article-title":"Montelukast does not increase the risk of neuropsychiatric disease in children with asthma: a nationwide population-based cohort study.","volume":"143","author":"Liu","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"zoi251558r21","first-page":"115","article-title":"Asthma and mood disorders.","volume":"1","author":"Kewalramani","year":"2008","journal-title":"Int J Child Health Hum Dev"},{"key":"zoi251558r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2022.108120","article-title":"Cerner real-world data (CRWD) \u2013 A de-identified multicenter electronic health records database.","volume":"42","author":"Ehwerhemuepha","year":"2022","journal-title":"Data Brief"},{"issue":"6","key":"zoi251558r34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/23808993.2019.1690396","article-title":"How does race and ethnicity effect the precision treatment of asthma?","volume":"4","author":"Zhang","year":"2019","journal-title":"Exper Rev Precis Med Drug Dev"},{"issue":"3","key":"zoi251558r35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MLR.0000000000000064","article-title":"Assessing the impact of propensity score estimation and implementation on covariate balance and confounding control within and across important subgroups in comparative effectiveness research.","volume":"52","author":"Girman","year":"2014","journal-title":"Med Care"},{"issue":"3","key":"zoi251558r36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00001648-200105000-00005","article-title":"Low P values or narrow confidence intervals: which are more durable?","volume":"12","author":"Poole","year":"2001","journal-title":"Epidemiology"},{"issue":"11","key":"zoi251558r37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"7","key":"zoi251558r38","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/02770903.2023.2293064","article-title":"Assessing the risk of intentional self-harm in montelukast users: an updated Sentinel system analysis using ICD-10 coding.","volume":"61","author":"Apata","year":"2024","journal-title":"J Asthma"},{"issue":"4","key":"zoi251558r39","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jaci.2008.07.012","article-title":"Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials.","volume":"122","author":"Holbrook","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"zoi251558r40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/pds.3758","article-title":"Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study.","volume":"24","author":"Ali","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi251558r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13643","article-title":"Analysis of neuropsychiatric diagnoses after montelukast initiation.","volume":"5","author":"Paljarvi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zoi251558r43","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2022.16946","article-title":"Screening for depression and suicide risk in children and adolescents: US Preventive Services Task Force recommendation statement.","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"zoi251558r44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jamia.2010.007237","article-title":"Data from clinical notes: a perspective on the tension between structure and flexible documentation.","volume":"18","author":"Rosenbloom","year":"2011","journal-title":"J Am Med Inform Assoc"},{"key":"zoi251558r45","doi-asserted-by":"publisher","first-page":"h1885","DOI":"10.1136\/bmj.h1885","article-title":"Development of phenotype algorithms using electronic medical records and incorporating natural language processing.","volume":"350","author":"Liao","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"zoi251558r46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/aje\/kwab299","article-title":"Use of linked databases for improved confounding control: considerations for potential selection bias.","volume":"191","author":"Sun","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi251558r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17319","article-title":"Health insurance type and outpatient specialist care among children with asthma.","volume":"7","author":"Geissler","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi251558r48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1472-6947-14-51","article-title":"Hidden in plain sight: bias towards sick patients when sampling patients with sufficient electronic health record data for research.","volume":"14","author":"Rusanov","year":"2014","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"zoi251558r49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40264-015-0360-2","article-title":"Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase.","volume":"39","author":"Aldea Perona","year":"2016","journal-title":"Drug Saf"},{"issue":"7","key":"zoi251558r50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/jpepsy\/jsv012","article-title":"Systematic review and meta-analysis of anxious and depressive symptoms in caregivers of children with asthma.","volume":"40","author":"Easter","year":"2015","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"zoi251558r51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-019-00870-x","article-title":"Exploratory study of signals for asthma drugs in children, using the EudraVigilance database of spontaneous reports.","volume":"43","author":"Baan","year":"2020","journal-title":"Drug Saf"},{"issue":"2","key":"zoi251558r52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/01.DBP.0000267557.80834.e5","article-title":"Developmental and behavioral comorbidities of asthma in children.","volume":"28","author":"Blackman","year":"2007","journal-title":"J Dev Behav Pediatr"},{"key":"zoi251558r53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.prrv.2019.03.009","article-title":"Inhaled corticosteroid-phobia and childhood asthma: current understanding and management implications.","volume":"33","author":"Hui","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"6","key":"zoi251558r54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jpsychores.2015.10.003","article-title":"Beliefs about medication predict the misattribution of a common symptom as a medication side effect\u2013evidence from an analogue online study.","volume":"79","author":"Heller","year":"2015","journal-title":"J Psychosom Res"},{"key":"zoi251558r1","unstructured":"Focus area: product safety surveillance. US Food and Drug Administration. Accessed July 15, 2024. https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/focus-area-product-safety-surveillance"},{"key":"zoi251558r2","unstructured":"FDA\u2019s Sentinel Initiative. US Food and Drug Administration. Accessed September 21, 2024. https:\/\/www.fda.gov\/safety\/fdas-sentinel-initiative"},{"key":"zoi251558r4","unstructured":"How Sentinel gets its data. Accessed September 5, 2024. https:\/\/www.sentinelinitiative.org\/about\/how-sentinel-gets-its-data"},{"key":"zoi251558r22","unstructured":"FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. US Food and Drug Administration. Accessed April 17, 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug"},{"key":"zoi251558r23","unstructured":"Singulair (montelukast sodium) tablets, chewable tablets, and oral granules. US Food and Drug Administration. Accessed April 17, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020829s055,020830s056,021409s031lbl.pdf"},{"key":"zoi251558r24","unstructured":"Asthma management guidelines: focused updates 2020. National Heart, Blood, and Lung Institute. Accessed May 16, 2023. https:\/\/www.nhlbi.nih.gov\/health-topics\/asthma-management-guidelines-2020-updates"},{"key":"zoi251558r25","unstructured":"Early communication about an ongoing safety review of montelukast (Singulair). US Food and Drug Administration. Accessed April 17, 2023. https:\/\/wayback.archive-it.org\/7993\/20170406045734\/https:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070618.htm"},{"key":"zoi251558r26","unstructured":"45 CFR part 46 subpart A. basic HHS policy for protection of human research subjects. Code of Federal Regulations. Accessed September 21, 2024. https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-A\/part-46\/subpart-A#46.102"},{"key":"zoi251558r27","unstructured":"Rosati? K, Jorgensen? N, Soliz? M, Evans? BJ. Sentinel Initiative principles and policies: HIPAA and Common Rule compliance in the Sentinel Initiative. Sentinel Initiative. 2018. Accessed September 21, 2024. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/communications\/publications-presentations\/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf"},{"key":"zoi251558r28","unstructured":"Inclusion of semi-structured and unstructured electronic health record (EHR) data in confounding adjustment and outcome ascertainment. Sentinel Initiative. Accessed March 31, 2024. https:\/\/www.sentinelinitiative.org\/methods-data-tools\/methods\/inclusion-semi-structured-and-unstructured-electronic-health-record-ehr"},{"key":"zoi251558r30","unstructured":"Population health. Oracle. Accessed September 8, 2024. https:\/\/www.oracle.com\/health\/population-health\/real-world-data\/"},{"key":"zoi251558r31","unstructured":"Mortality data in healthcare analytics. Datavant. Accessed November 5, 2025. https:\/\/www.datavant.com\/white-papers\/mortality-data-in-healthcare-analytics"},{"key":"zoi251558r32","unstructured":"Natural language processing in pharmacoepidemiology: lessons from the Multi-Source Observational Safety study for Advanced Information Classification Using NLP (MOSAIC-NLP). Sentinel Initiative. August 26, 2024. Accessed July 27, 2025. https:\/\/www.sentinelinitiative.org\/news-events\/publications-presentations\/natural-language-processing-pharmacoepidemiology-lessons"},{"key":"zoi251558r33","unstructured":"Huang? Z, Research? B, Xu? W, Baidu? KY. Bidirectional LSTM-CRF models for sequence tagging.? arXiv. Preprint posted online August 9, 2015. doi:10.48550\/arXiv.1508.01991"},{"key":"zoi251558r42","unstructured":"Suicidality in children and adolescents being treated with antidepressant medications. US Food and Drug Administration. 2018. Accessed September 5, 2024. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/suicidality-children-and-adolescents-being-treated-antidepressant-medications"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2844976\/jaffe_2026_oi_251558_1770311117.3612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:30:42Z","timestamp":1770913842000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2844976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.58433","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}